MedTrace Logo

A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients

NCT06402981 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-05-07

No results posted yet for this study

Summary

The goal of this observational study is to investigate the risk factors of PD-1/PD-L1 inhibitor-associated liver injury, to construct a prediction model for the occurrence of liver injury. The main questions it aims to answer are:

* Exploring risk factors for liver injury.
* Constructing a Predictive Model for the Occurrence of Liver Injury in PD-1/PD-L1 Inhibitor-Related Liver Injury.
* Improving immunotherapy protocols for lung cancer patients.

Conditions

  • Immune Checkpoint Inhibitors
  • Liver Injury

Interventions

OTHER

High risk prediction model for liver injury

Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Jiajia Chen · Zhejiang University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06402981 on ClinicalTrials.gov